Skip to main content
Clinical Trials/NCT02284932
NCT02284932
Unknown
Not Applicable

Muscle Atrophy In Patients With Chronic Obstructive Pulmonary Disease

Laval University1 site in 1 country36 target enrollmentSeptember 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Obstructive Pulmonary Disease
Sponsor
Laval University
Enrollment
36
Locations
1
Primary Endpoint
Decrease of protein degradation in muscles of wasted COPD patients
Last Updated
9 years ago

Overview

Brief Summary

Limb muscle dysfunction, characterized by atrophy and weakness, is amongst the most troublesome systemic consequences of chronic obstructive pulmonary disease (COPD) leading to poor functional status and premature mortality.

One prevailing hypothesis stipulates that the deterioration in muscle structure and function during COPD results from a spillover of inflammatory mediators from the lungs to the systemic circulation and then to the muscles.

Detailed Description

The investigators objective is to investigate the impact of COPD on key signaling pathways involved in the muscle atrophy. Moderate to severe COPD patients (FEV1 under 60% of predicted) and healthy controls will be recruited. All of the investigators patients will undergo a thorough baseline assessment in pulmonary capacity, muscle force and body composition. Blood sampling and biopsy of the quadriceps will be done. Key proteins of signaling intramuscular pathways involved in protein synthesis and degradation will be measured in the quadriceps.

Registry
clinicaltrials.gov
Start Date
September 2011
End Date
September 2018
Last Updated
9 years ago
Study Type
Observational
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Annie Dubé

Professionelle de recherche

Laval University

Eligibility Criteria

Inclusion Criteria

  • COPD with an FEV1 of under 60% of predicted
  • non-smoker
  • between 55 and 75 years old

Exclusion Criteria

  • all inflammatory disease (HIV, cancer, renal and cardiac deficiency)
  • hormonal dysregulation
  • inferior limb pathology
  • neuromuscular pathology
  • history of tobacco or alcool abuse
  • oxygen dependent
  • recent exacerbation (2 months) of the symptoms of COPD

Outcomes

Primary Outcomes

Decrease of protein degradation in muscles of wasted COPD patients

Time Frame: At baseline (COPD in a stable state of the disease)

Secondary Outcomes

  • Increase of protein synthesis in muscles of wasted COPD patients(At baseline (COPD in a stable state of the disease))

Study Sites (1)

Loading locations...

Similar Trials